Placida is the brand name of a drug that combines flupenthixol and melitracen. It is intended to be used as an antidepressant but is banned in some countries, including the United States, due to safety concerns. It is also sold under the brand names Deanxit, Franxit and Restfull. The brand Placida is manufactured and sold by the company Mankind Pharma Limited, New Delhi, India.
The combination of flupenthixol and melitracen was developed to treat various forms of depression, bipolar illness, resistant migraines, and certain gastrointestinal conditions. The combination of the two drugs has the potential to cause serious neurological side effects. Common side effects of the combination include increased heart rate, fatigue, difficulty sleeping and gastrointestinal upset. The combination drug is habit-forming and can cause severe withdrawal symptoms if stopped suddenly.
Flupenthixol is used in some countries to treat schizophrenia. It is given as an intramuscular injection for this purpose. It is known to affect fertility and to cause health problems in babies born to mothers who have taken flupenthixol during pregnancy. It can also cause uncontrollable movements of mouth, jaw, arms and legs, a condition called tardive dyskinesia.
Melitracen is a tricyclic antidepressant that is used in Japan and some European countries to treat depression and anxiety. It has never been thoroughly tested for safety.